BR9914708A - Composição de matéria, dna, vetor de expressão, célula hospedeira, e, processo para preparar um composto farmacologicamente ativo - Google Patents

Composição de matéria, dna, vetor de expressão, célula hospedeira, e, processo para preparar um composto farmacologicamente ativo

Info

Publication number
BR9914708A
BR9914708A BR9914708-4A BR9914708A BR9914708A BR 9914708 A BR9914708 A BR 9914708A BR 9914708 A BR9914708 A BR 9914708A BR 9914708 A BR9914708 A BR 9914708A
Authority
BR
Brazil
Prior art keywords
peptide
preparing
pharmacologically active
dna
host cell
Prior art date
Application number
BR9914708-4A
Other languages
English (en)
Inventor
Ulrich Feige
Chuan-Fa Liu
Janet C Cheetham
Thomas C Boone
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26802505&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9914708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR9914708A publication Critical patent/BR9914708A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

"COMPOSIçãO DE MATéRIA, DNA, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, E, PROCESSO PARA PREPARAR UM COMPOSTO FARMACOLOGICAMENTE ATIVO". A presente invenção diz respeito à fusão de domínios Fc com peptídeos biologicamente ativos e a um processo para preparar agentes farmacêuticos usando-se os peptídeos biologicamente ativos. Nesta invenção, os compostos farmacologicamente ativos são preparados por um processo que compreende: a) selecionar pelo menos um peptídeo que module a atividade de uma proteína de interesse; e b) preparar um agente farmacológico que compreenda um domínio Fc covalentemente ligado a pelo menos um aminoácido do peptídeo selecionado. A ligação ao veículo aumenta a meia vida do peptídeo que de outro modo seria rapidamente degradado in vivo. O veículo preferido é um domínio Fc. O peptídeo é preferivelmente selecionado pela exposição de fago, exposição de E. coli, exposição de ribossoma, seleção RNA-peptídeo ou seleção química-peptídeo.
BR9914708-4A 1998-10-23 1999-10-25 Composição de matéria, dna, vetor de expressão, célula hospedeira, e, processo para preparar um composto farmacologicamente ativo BR9914708A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10537198P 1998-10-23 1998-10-23
US09/428,082 US6660843B1 (en) 1998-10-23 1999-10-22 Modified peptides as therapeutic agents
PCT/US1999/025044 WO2000024782A2 (en) 1998-10-23 1999-10-25 Modified peptides, comprising an fc domain, as therapeutic agents

Publications (1)

Publication Number Publication Date
BR9914708A true BR9914708A (pt) 2002-07-16

Family

ID=26802505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914708-4A BR9914708A (pt) 1998-10-23 1999-10-25 Composição de matéria, dna, vetor de expressão, célula hospedeira, e, processo para preparar um composto farmacologicamente ativo

Country Status (29)

Country Link
US (7) US6660843B1 (pt)
EP (1) EP1144454B2 (pt)
JP (9) JP2003512011A (pt)
KR (3) KR100753305B1 (pt)
CN (8) CN1781946A (pt)
AT (1) ATE380828T1 (pt)
AU (3) AU767725B2 (pt)
BG (1) BG65721B1 (pt)
BR (1) BR9914708A (pt)
CA (1) CA2347131C (pt)
CY (1) CY1107881T1 (pt)
CZ (1) CZ304242B6 (pt)
DE (1) DE69937752T3 (pt)
DK (1) DK1144454T4 (pt)
EA (1) EA005404B1 (pt)
ES (1) ES2299278T5 (pt)
HK (2) HK1042097B (pt)
HU (1) HU229485B1 (pt)
IL (2) IL142365A0 (pt)
MX (1) MXPA01003873A (pt)
NO (1) NO331733B1 (pt)
NZ (2) NZ510888A (pt)
PL (1) PL211164B1 (pt)
PT (1) PT1144454E (pt)
RS (1) RS51852B (pt)
SI (1) SI1144454T2 (pt)
SK (1) SK287037B6 (pt)
WO (1) WO2000024782A2 (pt)
ZA (1) ZA200102753B (pt)

Families Citing this family (551)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PT2319928E (pt) 1998-10-23 2013-06-28 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2000047740A2 (en) * 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
DK1582204T3 (da) * 1999-03-03 2013-11-04 Lilly Co Eli Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
KR20020003864A (ko) * 1999-03-03 2002-01-15 피터 지. 스트링거 에키노칸딘/탄수화물 착물
DE60028970T2 (de) 1999-07-02 2007-02-15 Genentech Inc., San Francisco An her2 bindende peptidverbindungen
WO2001001749A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. FVIIa ANTAGONISTS
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1274723A4 (en) * 1999-07-29 2003-10-01 Univ Johns Hopkins ACTIVATION OF PEPTID-PRO DRUGS BY hK2
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PT1290013E (pt) 2000-04-21 2006-06-30 Amgen Inc Derivados dos peptidos apo-ai/aii
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
CA2410453A1 (en) * 2000-05-26 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
CA2410526C (en) * 2000-06-02 2012-04-17 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
AU8881201A (en) * 2000-09-05 2002-03-22 Amgen Inc Tnf receptor-like molecules and uses thereof
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1370589B1 (en) 2000-12-05 2006-03-15 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
ES2387546T3 (es) * 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
CN103232539B (zh) * 2001-06-26 2015-06-03 安姆根弗里蒙特公司 抗opgl抗体
WO2003029436A2 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030113270A1 (en) * 2001-12-14 2003-06-19 Clark Abbot F. Vasoactive intestinal peptides for glaucomatous retinopathy
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CA2490409A1 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
ATE401345T1 (de) * 2002-08-06 2008-08-15 Aplagen Gmbh Synthetische mimetika von physiologischen bindungsmolekülen
WO2004014951A2 (en) * 2002-08-06 2004-02-19 Aplagen Gmbh Binding molecules
CA2496795C (en) 2002-08-28 2014-06-03 Paul B. Burton Compositions and methods for treating cardiovascular disease
WO2004022718A2 (en) 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
CN100348618C (zh) 2002-09-11 2007-11-14 弗雷泽纽斯卡比德国有限公司 生产羟烷基淀粉衍生物的方法
PT1542714E (pt) 2002-09-18 2014-06-23 Janssen Pharmaceuticals Inc Métodos para aumentar a produção de células estaminais plaquetárias e hematopoiéticas
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
PT1558643E (pt) * 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
AR042545A1 (es) * 2002-12-20 2005-06-22 Amgen Inc Agentes ligantes que inhiben la miostatina
US7125849B2 (en) * 2003-01-14 2006-10-24 The Scripps Research Institute Peptide-based angiogenesis inhibitors and methods of use thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004208865B2 (en) * 2003-02-06 2010-06-17 Merck Patent Gmbh Peptidic sulfonamides
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2004108885A2 (en) * 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2298347B1 (en) * 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
AU2004238364A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
JP4266028B2 (ja) 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
PT1625156E (pt) * 2003-05-12 2013-01-09 Affymax Inc Novos péptidos que se fixam ao receptor da eritropoietina
JP4866238B2 (ja) * 2003-06-20 2012-02-01 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー Ｂ型肝炎ウィルスの新規の表面タンパク質（ＨＢｓＡｇ）変異体
CN101124240B (zh) 2003-07-18 2013-12-18 安姆根有限公司 肝细胞生长因子的特异性结合物
WO2005012530A2 (en) 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP4809767B2 (ja) * 2003-08-18 2011-11-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発現ベクター、ポリペプチドディスプレイライブラリ、並びにそれらの作製及び使用方法
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
JP4767857B2 (ja) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾイミダゾール化合物
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
US8846874B2 (en) * 2003-11-13 2014-09-30 Hanmi Science Co., Ltd IgG Fc fragment for a drug carrier and method for the preparation thereof
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP4982183B2 (ja) 2003-12-12 2012-07-25 ジェネンコー・インターナショナル・インク Ｃａｂ分子
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
AU2005225513B2 (en) 2004-03-11 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
EP2279752A3 (en) * 2004-03-11 2011-08-24 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
AU2005231822B2 (en) * 2004-04-02 2011-07-21 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
EP1735350B1 (en) 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
JP2005309295A (ja) * 2004-04-26 2005-11-04 Nec Corp 光増幅素子、光増幅装置および光増幅システム
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050281799A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
KR101100059B1 (ko) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
WO2006014567A2 (en) 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
WO2007001332A2 (en) * 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
CN101103045B (zh) * 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
EP1812472A1 (en) * 2004-11-04 2007-08-01 Genentech, Inc. Polypeptides that bind baff and/or april
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070110760A1 (en) * 2005-01-14 2007-05-17 Monroe John G Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
US8053415B2 (en) * 2005-01-21 2011-11-08 Washington University In St. Louis Compounds having RD targeting motifs
WO2006088245A1 (ja) * 2005-02-18 2006-08-24 The University Of Tokushima ポリオキシアルキレン鎖含有脂質誘導体及び該誘導体を含有する脂質膜構造体
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8101728B2 (en) 2005-04-28 2012-01-24 Danisco Us Inc. TAB molecules
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
EA200800109A1 (ru) * 2005-06-23 2008-06-30 Аплаген Гмбх Суправалентные соединения
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
CN103172739A (zh) * 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
KR20140097582A (ko) 2005-07-18 2014-08-06 암젠 인크 인간 항-ｂ7ｒｐ1 중화 항체
EP2298815B1 (en) * 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2619771C (en) * 2005-08-16 2012-05-22 Hanmi Pharmaceutical Co., Ltd. A method for the mass production of immunoglobulin fc region deleted initial methionine residues
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2620886C (en) * 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
KR100780405B1 (ko) * 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 알파 나선형 펩티드를 이용한 ｒｎａ 특이적 결합 펩티드탐색 방법
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
EP1928916A2 (en) * 2005-09-29 2008-06-11 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US8445642B1 (en) * 2005-10-13 2013-05-21 The United States Of America As Represented By The Secretary Of Agriculture Methods to differentiate protein conformers
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1948785B1 (en) * 2005-10-24 2014-01-15 Janssen Biotech, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
DK2500360T3 (en) * 2005-10-31 2015-10-26 Oncomed Pharm Inc Compositions and methods for the diagnosis and treatment of cancer
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007064972A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
ES2524984T3 (es) 2005-11-30 2014-12-16 Abbvie Inc. Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
ES2434494T3 (es) 2005-12-08 2013-12-16 Amgen, Inc. Células huésped mejoradas y métodos de cultivo
EP2377886A1 (en) 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
WO2007100937A2 (en) * 2006-01-19 2007-09-07 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CA2646391A1 (en) * 2006-03-22 2007-09-27 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
CA2648035A1 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
EP2010566B2 (en) 2006-04-05 2017-07-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ES2349024T3 (es) * 2006-04-11 2010-12-21 Csl Behring Gmbh Metodo para aumentar la recuperacion in vivo de polipeptidos terapeuticos.
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2652570A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
WO2007146968A2 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
PL2059536T3 (pl) 2006-08-14 2014-07-31 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
EP2074139B1 (en) 2006-09-08 2013-10-23 Amgen, Inc Il-1 family variants
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
CL2007002609A1 (es) * 2006-09-08 2008-04-18 Genentech Inc Antagonista de wnt que comprende un componente del dominio frizzled y un dominio fc; secuencia de acidos nucleicos que lo codifica; composicion que lo comprende; y su uso para tratar trastornos de proliferacion celular.
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
US20100150834A1 (en) * 2006-09-15 2010-06-17 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100297218A1 (en) * 2006-09-20 2010-11-25 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US20080123083A1 (en) * 2006-11-29 2008-05-29 The Regents Of The University Of Michigan System and Method for Photoacoustic Guided Diffuse Optical Imaging
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
KR101542752B1 (ko) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
JP2010520855A (ja) 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
EP2109457B1 (en) * 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
DK2152736T3 (en) 2007-05-03 2017-09-18 Lysomab Gmbh Complement factor H-derived short-consensus repeat (SCR) antibody constructs
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
CA2689518A1 (en) * 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. A novel bone mass increasing agent
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
KR20100040937A (ko) 2007-07-26 2010-04-21 암젠 인크 변형된 레시틴-콜레스테롤 아실트랜스퍼라제 효소
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
WO2009012600A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins
JP2010535788A (ja) * 2007-08-09 2010-11-25 シントニックス・ファーマシューティカルズ・インコーポレーテッド 免疫調節性ペプチド
WO2009026122A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
EP4248976A3 (en) 2007-08-23 2024-04-10 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009033212A1 (en) * 2007-09-11 2009-03-19 Christopher Hovens The use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
JP2010540654A (ja) * 2007-10-02 2010-12-24 ポテンシア ファーマシューティカルズ， インコーポレイテッド ゲルからのコンプスタチンアナログの持続的送達
US7829735B2 (en) 2007-10-26 2010-11-09 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
CA2958185C (en) 2007-12-26 2020-08-25 Xencor, Inc. Fc variants with altered binding to fcrn
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
ES2500066T3 (es) 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN101518644B (zh) * 2008-02-26 2011-07-13 上海交通大学医学院附属第九人民医院 Ang-2及其基因在制药中的应用
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
MX2010012142A (es) 2008-05-09 2011-04-05 Abbott Gmbh & Co Kg Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
CA2731546C (en) 2008-07-23 2013-11-19 Hanmi Holdings Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2168590A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
CN105079805A (zh) * 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
KR101778134B1 (ko) 2008-11-26 2017-09-13 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
US20120121537A1 (en) * 2009-01-12 2012-05-17 Chaomin Sun Methods and Compositions for Inhibiting Hepatitis C Virus Replication
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP3235509A1 (en) 2009-03-05 2017-10-25 AbbVie Inc. Il-17 binding proteins
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
CA2754961C (en) * 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
US10702583B2 (en) * 2009-03-11 2020-07-07 Promedior, Inc. Treatment methods for autoimmune disorders
MX347291B (es) 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
US20120018338A1 (en) 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
JO3469B1 (ar) 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
MX2011013457A (es) * 2009-06-15 2012-05-08 Biokine Therapeutics Ltd Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
DK2443144T3 (en) * 2009-06-17 2015-11-23 Promedior Inc SAP variants and their application
CA2764835A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
BRPI1011940B8 (pt) 2009-06-22 2021-08-03 Amgen Inc método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero
MX2011013417A (es) 2009-06-25 2012-03-29 Amgen Inc Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero.
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
IT1395137B1 (it) 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP2013507928A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN113528485A (zh) 2009-11-02 2021-10-22 华盛顿大学 治疗性核酸酶组合物和方法
US8759293B2 (en) * 2009-11-13 2014-06-24 Grifols Therapeutics Inc. von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
WO2011060371A2 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
PL2510001T3 (pl) 2009-12-08 2016-06-30 Abbvie Deutschland Monoklonalne przeciwciało przeciwko białku RGM A do zastosowania w leczeniu zwyrodnienia warstwy włókien nerwowych siatkówki (RNFL)
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
EP2526119B1 (en) * 2010-01-19 2018-05-30 President and Fellows of Harvard College Engineered opsonin for pathogen detection and treatment
US20110189084A1 (en) 2010-01-28 2011-08-04 Raptor Pharmaceutical Inc. Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates
EP2536754A1 (en) 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
JP5964249B2 (ja) 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
BR112012022229A2 (pt) 2010-03-03 2016-07-05 Univ British Columbia epítopo beta amilóide epecíficio para oligômero e anticorpos
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN102971340A (zh) 2010-03-29 2013-03-13 酵活有限公司 具有增强的或抑制的效应子功能的抗体
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
EP2927242A1 (en) 2010-04-09 2015-10-07 Amgen, Inc Btnl9 proteins, nucleic acids, and antibodies and uses thereof
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2011143614A1 (en) 2010-05-14 2011-11-17 Amgen Inc. Enhanced death receptor agonists
TWI615405B (zh) 2010-05-14 2018-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
WO2012012141A1 (en) 2010-06-30 2012-01-26 Amgen Inc. Scnn1a/tnfrsf1a fusion proteins in cancer
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
ES2873253T3 (es) 2010-09-28 2021-11-03 Amryt Pharmaceuticals Inc Leptinas altamente solubles
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
JP6009455B2 (ja) 2010-12-21 2016-10-19 アッヴィ・インコーポレイテッド Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
SG192047A1 (en) 2011-01-24 2013-08-30 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
BR112013019499B1 (pt) 2011-02-04 2023-01-10 Genentech, Inc. Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2681238A2 (en) 2011-02-28 2014-01-08 Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo Apoptosis-inducing molecules and uses therefor
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
MX2013011706A (es) 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
KR101747489B1 (ko) * 2011-04-25 2017-06-15 다이호야쿠힌고교 가부시키가이샤 ｐＨ 응답성 펩티드를 포함하는 나노 입자
SG10201913930UA (en) 2011-04-29 2020-03-30 Univ Washington Therapeutic nuclease compositions and methods
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
RU2739209C2 (ru) 2011-06-10 2020-12-21 Ханми Сайенс Ко., Лтд. Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения
DK2721062T3 (en) * 2011-06-17 2019-02-25 Hanmi Science Co Ltd Conjugate comprising oxyntomodulin and an immunoglobulin fragment as well as its use
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
KR102042982B1 (ko) 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용
EP2737905B1 (en) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
EP2744828A4 (en) 2011-08-16 2014-12-31 Univ Emory JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
CA2846030A1 (en) * 2011-08-31 2013-03-07 Indi Molecular, Inc. Vegf-specific capture agents, compositions and methods of using and making
WO2013033600A1 (en) 2011-09-02 2013-03-07 Amgen Inc. Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
CN104093744A (zh) 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
SG11201401796SA (en) 2011-10-24 2014-10-30 Abbvie Inc Bispecific immunobinders directed against tnf and il-17
KR102091294B1 (ko) 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
AU2012352168C1 (en) 2011-12-14 2018-01-25 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
CA2858099C (en) 2011-12-22 2020-12-15 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
EP3553075A1 (en) 2012-01-23 2019-10-16 Washington University Goggle imaging systems and methods
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
US9809641B2 (en) * 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
KR20150030706A (ko) 2012-06-11 2015-03-20 암젠 인코퍼레이티드 이중 수용체 길항 항원-결합 단백질 및 그것의 사용
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
JP6309002B2 (ja) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
EP2875046B1 (en) 2012-07-19 2020-02-26 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
BR112015008663B1 (pt) * 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
CA2890324C (en) 2012-11-06 2021-02-23 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PT2928476T (pt) 2012-12-07 2018-05-10 Glycomimetics Inc Compostos, composições e métodos que utilizam antagonistas de e-selectina para mobilização de células hematopoiéticas
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
WO2014110503A1 (en) * 2013-01-11 2014-07-17 Case Western Reserve University Methods and compositions for treating cancer
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
EP2950885B1 (en) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
TWI708782B (zh) * 2013-02-26 2020-11-01 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
JP6077641B2 (ja) * 2013-03-08 2017-02-08 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
DK2964255T3 (da) 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
EP2970408B1 (en) 2013-03-12 2018-01-10 Amgen Inc. Potent and selective inhibitors of nav1.7
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
CN105188733B (zh) * 2013-03-13 2020-05-08 建新公司 包含pdgf和vegf结合部分的融合蛋白及其使用方法
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
JP6581572B2 (ja) 2013-06-07 2019-09-25 デューク ユニバーシティ 補体因子ｈ阻害薬
EP3013422A1 (en) 2013-06-28 2016-05-04 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US20160166660A1 (en) 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
EP3024492A2 (en) 2013-07-25 2016-06-01 Novartis AG Bioconjugates of synthetic apelin polypeptides
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
DK3046933T3 (da) * 2013-09-18 2019-05-13 Bcn Peptides Sa Cortistatin-analoger til behandling af inflammations- og/eller immunsygdomme
WO2015057820A2 (en) * 2013-10-15 2015-04-23 Roberts S Kenny Peptide constructs and well-defined aggregates thereof
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
JP6682438B2 (ja) 2014-01-09 2020-04-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッドＨａｄａｓｉｔ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｓｅｒｖｉｃｅｓ ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｔｄ． 癌治療のための改善された細胞組成物および方法
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
WO2015157595A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
MX2016014409A (es) 2014-05-06 2017-01-20 Genentech Inc Produccion de proteinas heteromultimericas usando celulas de mamifero.
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
WO2015191760A2 (en) 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
PL3157548T3 (pl) 2014-06-18 2022-01-17 Csl Behring Gmbh Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
MX2017004769A (es) 2014-10-15 2017-10-16 Amgen Inc Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas.
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
RU2702087C2 (ru) * 2014-12-22 2019-10-03 Лантхиопеп Б.В. Новые способы дисплея циклических пептидов на частицах бактериофага
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
TW201639596A (zh) 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
AU2016211242A1 (en) * 2015-01-30 2017-08-17 University Of Utah Research Foundation Dimeric collagen hybridizing peptides and methods of using
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
EP3265480B1 (de) * 2015-03-05 2021-03-24 Peter und Traudl Engelhorn-Stiftung zur Förderung der Lebenswissenschaften System zur präsentation von peptiden auf der zelloberfläche
EP3281010B1 (en) 2015-04-10 2020-12-30 The Regents of The University of California Methods of determining patient populations amenable to immunomodulatory treatment of cancer
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2016179350A1 (en) 2015-05-06 2016-11-10 Washington University Compounds having rd targeting motifs and methods of use thereof
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
MA42821A (fr) 2015-09-15 2018-07-25 Amgen Inc Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017059371A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
WO2017075189A1 (en) 2015-10-27 2017-05-04 University Of Massachusetts Factor h-fc immunotherapy
KR101826792B1 (ko) * 2015-10-29 2018-02-09 주식회사 와이바이오로직스 Dlk1의 세포 외 수용성 도메인을 유효성분으로 포함하는 지방간 또는 인슐린 저항성 증후군 예방 및 치료용 조성물
AU2016372026A1 (en) * 2015-12-15 2018-06-21 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
KR20180100135A (ko) 2015-12-17 2018-09-07 바이오카인 테라퓨틱스 리미티드 케모카인 활성, 키나아제 활성 및/또는 암세포 성장 억제용 저분자
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
US10806774B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
EP3400238B1 (en) 2016-01-07 2021-05-19 CSL Behring Lengnau AG Mutated von willebrand factor
KR20180132831A (ko) 2016-04-06 2018-12-12 시에스엘 리미티드 죽상동맥경화증의 치료 방법
US10662236B2 (en) * 2016-04-07 2020-05-26 Industry-University Cooperation Foundation Hanyang University Erica Campus Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides
WO2017179647A1 (ja) * 2016-04-14 2017-10-19 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ａｓｐｄ）結合阻害ペプチド、並びに評価及びスクリーニング方法
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
RU2764651C2 (ru) 2016-06-08 2022-01-19 Эббви Инк. Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
US11312745B2 (en) 2016-07-22 2022-04-26 Amgen Inc. Methods of purifying Fc-containing proteins
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
WO2018079702A1 (ja) 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ ラクトフェリン／アルブミン融合タンパク質及びその製造方法
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
EP3496742A4 (en) * 2016-12-01 2020-04-08 University Of South Florida PEPTICORPS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING EAR FIBRILLATION
EP3568411B1 (en) 2017-01-13 2024-03-06 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
CA3051801A1 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3054899A1 (en) 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2018184964A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
KR102649757B1 (ko) 2017-07-20 2024-03-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 5t4 및 4-1bb에 결합하는 항원 결합 단백질 및 관련 조성물 및 방법
KR20200059213A (ko) 2017-07-26 2020-05-28 잔센파마슈티카엔.브이. 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 방법
WO2019028012A2 (en) 2017-07-31 2019-02-07 Dana-Farber Cancer Institute, Inc. METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
US20210346513A1 (en) 2017-08-04 2021-11-11 Amgen Inc. Method of conjugation of cys-mabs
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
WO2019036626A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
KR20200101954A (ko) 2017-12-19 2020-08-28 메사추세츠 인스티튜트 오브 테크놀로지 항원-아주반트 커플링 시약 및 사용 방법
KR20190114907A (ko) * 2018-03-30 2019-10-10 한미약품 주식회사 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
JP2022512775A (ja) 2018-10-23 2022-02-07 アムジエン・インコーポレーテツド リアルタイム予測のためのラマン分光モデルの自動校正及び自動保守
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
EP3906062A1 (en) 2019-01-04 2021-11-10 Resolve Therapeutics, LLC Treatment of sjogren's disease with nuclease fusion proteins
CA3125552A1 (en) * 2019-01-07 2020-07-16 Cenna Biosciences Inc. Novel peptides and uses thereof
WO2020154585A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
MA54830A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Procédés d'atténuation des effets toxiques d'agents vésicants et de gaz caustiques
CN113660943A (zh) 2019-01-25 2021-11-16 詹森药业有限公司 增强对全身放射/化学暴露反应的对器官和血管损伤的保护、造血恢复以及存活的方法
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
KR20210127947A (ko) 2019-02-15 2021-10-25 저스트-에보텍 바이오로직스, 아이엔씨. 자동화된 바이오 제조 시스템, 설비 및 공정
EP3941580A1 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
EP3941581A2 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
IL288144B2 (en) 2019-05-15 2024-03-01 Alonbio Ltd Compounds to treat cancer, to inhibit chemokines and/or to kill cells
KR20220009984A (ko) 2019-05-17 2022-01-25 유니베르시태트 취리히 출혈성 뇌졸중 후 2차 신경학적 이상 반응을 치료하는데 사용하기 위한 합토글로빈
MX2021014534A (es) 2019-05-30 2022-02-11 Amgen Inc Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
JP2022538232A (ja) 2019-06-28 2022-09-01 アムジエン・インコーポレーテツド 抗ｃｇｒｐ受容体／抗ｐａｃ１受容体二重特異性抗原結合タンパク質
CN114072420A (zh) 2019-07-04 2022-02-18 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
JP2022545368A (ja) 2019-08-12 2022-10-27 アプティーボ リサーチ アンド デベロップメント エルエルシー ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
MX2022005566A (es) 2019-11-08 2022-07-19 Amgen Inc Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
EP4072598A4 (en) 2019-12-13 2024-02-21 Washington University St Louis NEAR-INFRARED FLUORESCENT DYES, FORMULATIONS AND ASSOCIATED METHODS
MX2022008654A (es) 2020-01-13 2022-08-18 Aptevo Res & Development Llc Formulaciones para productos terapeuticos proteicos.
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
US20230071627A1 (en) 2020-02-03 2023-03-09 Amgen Inc. Multivariate Bracketing Approach for Sterile Filter Validation
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins
US20230322955A1 (en) 2020-08-20 2023-10-12 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
EP4244246A1 (en) 2020-11-10 2023-09-20 Amgen Inc. Novel linkers of multispecific antigen binding domains
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法
KR20230117379A (ko) 2020-12-01 2023-08-08 압테보 리서치 앤드 디벨롭먼트 엘엘씨 이종이량체 psma 및 cd3-결합 이중특이적 항체
US20240101598A1 (en) 2020-12-18 2024-03-28 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4284407A1 (en) 2021-02-01 2023-12-06 CSL Behring AG Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
WO2022225921A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
CA3217518A1 (en) 2021-05-07 2022-11-10 Rebecca Butcher Expression system for producing a recombinant haptoglobin (hp) beta chain
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
EP4370555A1 (en) 2021-07-13 2024-05-22 TrueBinding, Inc. Methods of preventing protein aggregation
IL311797A (en) 2021-10-01 2024-05-01 Albert Einstein College Of Medicine Methods for increasing stem cell production
CA3234966A1 (en) 2021-10-14 2023-04-20 Teneobio, Inc. Mesothelin binding proteins and uses thereof
CA3236194A1 (en) 2021-10-27 2023-05-04 Amgen Inc. Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
WO2023180525A1 (en) 2022-03-24 2023-09-28 Richter Gedeon Nyrt. Method for the manufacture of biopharmaceuticals
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
IN150740B (pt) 1978-11-24 1982-12-04 Hoffmann La Roche
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4760067A (en) 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE470099B (sv) 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA1283661C (en) 1984-06-20 1991-04-30 Franz Jansen Imidazolides, process for their preparation and application as intermediates for the synthesis of cytotoxic conjugates
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
SE454885B (sv) 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0318512B1 (en) * 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1990005534A1 (en) 1988-11-23 1990-05-31 Genentech, Inc. Polypeptide derivatives
ES2176174T3 (es) 1988-12-22 2002-12-01 Genentech Inc Procedimiento de preparacion de polipeptidos solubles en agua.
WO1990006774A1 (en) 1988-12-22 1990-06-28 Xoma Corporation Hindered linking agents and methods
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2068320C (en) 1989-11-29 2000-10-17 Robert Hageman Production of recombinant human interleukin-1 inhibitor
DE59105962D1 (de) † 1990-01-23 1995-08-17 Merck Patent Gmbh Flüssigkristallines medium.
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5349053A (en) † 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU643141B2 (en) * 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5376367A (en) 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5569779A (en) 1991-12-23 1996-10-29 Albemarle Corporation Polyfunctional michael addition products
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
CA2118508A1 (en) † 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
AU5098393A (en) * 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
NZ247231A (en) * 1993-03-23 1994-10-26 Holyoake Ind Ltd Diffuser for air conditioning system; outlet air direction thermostatically controlled
US5958409A (en) 1993-07-30 1999-09-28 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5998172A (en) † 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
BR9408534A (pt) 1994-02-14 1997-08-05 Zymogenetics Inc Proteína isolada molécula de polinucleotídeos e de dna isolada vetor de expressão célula cultivada mam'fero não humano composição farmacêutica anticorpo sonda e processos para produzir uma proteina hematopoiética para estimular a produção de plaquetas em um mamifero e a proliferação celular para detectar em uma mistura de moléculas de dna uma molécula de dna e para purificar trombopoietina
CA2167090C (en) 1994-03-31 2002-05-14 Timothy D. Bartley Compositions and methods for stimulating megakaryocyte growth and differentiation
IL113617A (en) † 1994-05-06 2007-09-20 Florence Faure Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system
US6184205B1 (en) † 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
WO1996017942A1 (en) 1994-12-07 1996-06-13 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
WO1996023899A1 (en) 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
YU34196A (sh) 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
CZ291749B6 (cs) 1995-06-07 2003-05-14 Glaxo Group Limited Peptidová sloučenina, která se váže na thrombopoetinový receptor a aktivuje jej a farmaceutický prostředek
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
IL118524A (en) 1995-06-19 2004-02-19 Akzo Nobel Nv Peptides and pharmaceutical preparations containing them useful in the treatment of peptide tolerance
US5955574A (en) † 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
WO1997008553A1 (en) 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ATE448797T1 (de) 1996-02-09 2009-12-15 Amgen Inc Zusammensetzung enthaltend il-1ra als interleukin-1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5798246A (en) 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
EP0906419A2 (en) 1996-03-28 1999-04-07 Chiron Corporation Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1997043316A1 (en) † 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
DE69737229T2 (de) 1996-06-07 2008-01-31 Takeda Pharmaceutical Co. Ltd. Peptid mit cortistatin- oder somatostatin-aktivität, verfahren zu dessen herstellung und dessen verwendungen
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
EP0927045B1 (en) 1996-09-10 2005-12-14 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
ES2190543T3 (es) 1996-10-08 2003-08-01 Bisys B V U Procedimientos y sistemas que permiten seleccionar peptidos y proteinas que tienen una afinidad especifica respecto a un blanco.
US5958703A (en) * 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
JP4175668B2 (ja) 1996-12-20 2008-11-05 アムジエン・インコーポレーテツド Ｏｂ融合タンパク質組成物および方法
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
DE69807679T2 (de) 1997-04-17 2003-07-31 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
DE69827260T2 (de) 1997-07-24 2006-02-16 PerSeptive Biosystems, Inc., Framingham Konjugate von transportpeptiden und nukleinsäureanaloga und deren verwendung
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
CA2306246A1 (en) 1997-10-06 1999-04-15 Millennium Pharmaceuticals, Inc. Signal peptide containing proteins and uses therefor
EA200000409A1 (ru) 1997-10-10 2000-10-30 Сайтовиэ, Инк. Соединение, фармацевтическая композиция, способ ингибирования гибели клетки в одной клетке или ткани, способ лечения или снижения клеточной смерти, способ лечения или профилактики поликистозного заболевания почек или анемии/эритропоэза у животных, способ защиты органа или ткани млекопитающего от гибели клеток, способ снижения или профилактики гибели клеток в органе или ткани донора после их трансплантации, способ снижения или предотвращения гибели спермы или яйцеклеток
WO1999024076A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Salicylate derivatized therapeutic and diagnostic agents
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
WO2000047740A2 (en) * 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
DE60028970T2 (de) † 1999-07-02 2007-02-15 Genentech Inc., San Francisco An her2 bindende peptidverbindungen
AU6064400A (en) † 1999-07-02 2001-01-22 Genentech Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
AU3695801A (en) * 2000-02-11 2001-11-20 Amgen, Inc. Receptor from tnf family
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
CA2490409A1 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
KR20050033563A (ko) 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2005259537A1 (en) * 2004-06-25 2006-01-12 Licentia, Ltd. Tie receptor and tie ligand materials and methods for modulating female fertility
DK1838733T3 (da) * 2004-12-21 2011-11-28 Medimmune Ltd Antistoffer rettet mod angiopoietin-2 og anvendelser deraf

Also Published As

Publication number Publication date
AU767725C (en) 2000-05-15
IL142365A0 (en) 2002-03-10
JP2003512011A (ja) 2003-04-02
DE69937752T2 (de) 2008-12-24
CN100384879C (zh) 2008-04-30
SI1144454T1 (sl) 2008-04-30
NO331733B1 (no) 2012-03-12
AU2004200687A1 (en) 2004-03-18
US20040044188A1 (en) 2004-03-04
HUP0203506A3 (en) 2012-09-28
US7166707B2 (en) 2007-01-23
PT1144454E (pt) 2008-02-08
CA2347131C (en) 2012-11-27
EP1144454B2 (en) 2012-12-12
NZ510888A (en) 2004-01-30
US7186810B2 (en) 2007-03-06
MXPA01003873A (es) 2003-10-14
ZA200102753B (en) 2002-06-11
HU229485B1 (en) 2014-01-28
NO20011963L (no) 2001-06-21
JP2007091747A (ja) 2007-04-12
JP2007084558A (ja) 2007-04-05
JP2007084555A (ja) 2007-04-05
EP1144454A2 (en) 2001-10-17
AU2004200687B2 (en) 2007-05-10
US7169905B2 (en) 2007-01-30
BG105461A (en) 2003-04-30
AU1232200A (en) 2000-05-15
IL142365A (en) 2013-02-28
WO2000024782A2 (en) 2000-05-04
US20040053845A1 (en) 2004-03-18
CN1331701A (zh) 2002-01-16
US6660843B1 (en) 2003-12-09
US20040071712A1 (en) 2004-04-15
AU767725B2 (en) 2003-11-20
US7189827B2 (en) 2007-03-13
DE69937752D1 (de) 2008-01-24
CN1781945A (zh) 2006-06-07
JP2007089586A (ja) 2007-04-12
CZ304242B6 (cs) 2014-01-22
DK1144454T4 (da) 2013-01-14
DK1144454T3 (da) 2008-05-05
JP2007105044A (ja) 2007-04-26
CN100384880C (zh) 2008-04-30
NO20011963D0 (no) 2001-04-20
CN1721447A (zh) 2006-01-18
KR20010099706A (ko) 2001-11-09
CN1781946A (zh) 2006-06-07
CN1781947A (zh) 2006-06-07
SI1144454T2 (sl) 2013-04-30
JP2007084557A (ja) 2007-04-05
YU25901A (sh) 2005-07-19
EP1144454B1 (en) 2007-12-12
JP2007091746A (ja) 2007-04-12
KR20070050978A (ko) 2007-05-16
HK1042097B (zh) 2008-04-03
NZ528882A (en) 2005-06-24
JP2007084556A (ja) 2007-04-05
CN1908014A (zh) 2007-02-07
BG65721B1 (bg) 2009-08-31
KR100753305B1 (ko) 2007-08-29
DE69937752T3 (de) 2013-02-28
EA005404B1 (ru) 2005-02-24
RS51852B (sr) 2012-02-29
EA200100464A1 (ru) 2002-10-31
PL211164B1 (pl) 2012-04-30
US20040057953A1 (en) 2004-03-25
HK1042097A1 (en) 2002-08-02
CA2347131A1 (en) 2000-05-04
KR20070050977A (ko) 2007-05-16
ES2299278T3 (es) 2008-05-16
HUP0203506A2 (hu) 2003-02-28
ES2299278T5 (es) 2013-04-03
US20070049532A1 (en) 2007-03-01
CN1746189A (zh) 2006-03-15
PL366080A1 (en) 2005-01-24
KR100753303B1 (ko) 2007-08-29
SK287037B6 (sk) 2009-10-07
AU2004200690B2 (en) 2007-05-10
ATE380828T1 (de) 2007-12-15
CY1107881T1 (el) 2013-06-19
AU2004200690A1 (en) 2004-03-18
KR100753304B1 (ko) 2007-08-29
CN1746190A (zh) 2006-03-15
SK5252001A3 (en) 2002-12-03
AU2004200690C1 (en) 2009-04-09
WO2000024782A3 (en) 2002-06-06
CN1310948C (zh) 2007-04-18
HK1090932A1 (en) 2007-01-05
US20040087778A1 (en) 2004-05-06
AU2004200687C1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
BR9914708A (pt) Composição de matéria, dna, vetor de expressão, célula hospedeira, e, processo para preparar um composto farmacologicamente ativo
WO2001083525A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
Cruz et al. . mu.-Conotoxin GIIIA, a peptide ligand for muscle sodium channels: chemical synthesis, radiolabeling and receptor characterization
BR0207576A (pt) Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
Ng et al. Hydrochloric acid hydrolysis of proteins and determination of tryptophan by reversed-phase high-performance liquid chromatography
BRPI0516011A (pt) moléculas fc modificadas
Williams et al. Fibronectin. Effect of disulfide bond reduction on its physical and functional properties.
ATE206433T1 (de) Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren
US6316409B1 (en) Modified ligands of calcium-dependent binding proteins
Acosta et al. Facile solid-phase synthesis of head-side chain cyclothiodepsipeptides through a cyclative cleavage from MeDbz-resin
NO20025064L (no) RGO koblet til peptider
BR0116122A (pt) Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
Williams et al. A photoaffinity scan maps regions of the p85 SH2 domain involved in phosphoprotein binding.
Takenaga et al. Bcl6-dependent transcriptional repression by BAZF
Blumenthal et al. Structure and action of heteronemertine polypeptide toxins. Primary structure of Cerebratulus lacteus toxin B-IV.
US20060217302A1 (en) Paralytic peptide for use in neuromuscular therapy
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
Grasso et al. An explanation for the disparate effects of synthetic peptides corresponding to human follicle-stimulating hormone β-subunit receptor binding regions (33-53) and (81-95) and their serine analogs on steroidogenesis in cultured rat Sertoli cells
Sato et al. Use of thiosulfonate for the protection of thiol groups in peptide ligation by the thioester method
BR9814433A (pt) "beta-lipotropina e usos da mesma"
Goolcharran Deamidation and diketopiperazine formation in model peptides and recombinant human vascular endothelial growth factor
Weiler Interaction of saposin C with glucocerebrosidase.
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O C/C 13, 22, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.